Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

IR Calendar

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

2025 Annual and Special Meeting of Shareholders

May 27, 2025 • 10:00 am EDT
The Notice of 2025 Annual and Special Meeting of Shareholders
PDF
Proxy Statement
PDF
The Annual Report to Shareholders on Form 10-K
PDF
Form of Proxy
PDF
Notice of Reconvened Meeting
PDF
LUMI User Guide
PDF
Audio
Webcast
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences